Navigation Links
Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection

other agents in this challenging setting."

Preclinical studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident). In these studies, Valortim has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection when administered at the time of exposure, at doses as low as 1.0 mg/kg. When administered to rabbits after the development of symptoms, Valortim also improved survival as late as 48 hours post-exposure as compared to controls.

"We believe that there are distinct characteristics of Valortim that make it an ideal choice for military and civilian protection against an anthrax bioterrorist attack," commented David P. Wright, President and Chief Executive Officer of PharmAthene. "As our Phase I results have demonstrated, a single intramuscular dose of Valortim produces levels of antibodies in humans that correspond to protective levels in animal models and is well tolerated. Based on the impressive human safety and animal efficacy data collected to date, we believe that Valortim could meet the needs of the U.S. Government and could ultimately be selected for inclusion in the Strategic National Stockpile to provide protection to the American public."

About Valortim

Valortim (MDX-1303) is a fully human antibody designed to protect against anthrax infection, including inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness by attaching to cells in the infected person, and then is
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Cethromycin Shown Effective Against Anthrax in Study
3. Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
4. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
5. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
6. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

Post Your Comments:
(Date:11/25/2009)...AND,Colo.,Nov.25/PRNewswire-FirstCall/--HeskaCorpo...ddiagnosticandspecialtyproductstotheveterinaryindu...orporationforthesupplyofbloodgasproductsandaffilia... http://www.newscom.com/cgi-bin/prnh/20000622/HESK...innovatinginthefieldofadvancedpoint-of-carediagnos...
(Date:11/25/2009)...,Pa.,Nov.25/PRNewswire/--BioTrendsResearchGroup,In... report,thefirstinamulti-phasesyndicatedmarketres...ch,sStelara,fromproductlaunchthroughthefirstsixmon...itativeinformationfrom75uniqueDermatologistsandqua...strialanduseofStelara,obstaclestouse,typicalpatien...
(Date:11/25/2009)...NGRIDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences...hromboticaptamerswithactivecontrolagents,announced...gatthePiperJaffray21stAnnualHealthCareConferenceat...ntationwillbegivenat1:10pm(EST)onTuesday,December1...emphasisontheleaddevelopmentprogram,theanticoagula...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Imagenetix Inc Announces Interview With Bloomberg Radio 13589 1Imagenetix Inc Announces Interview With Bloomberg Radio 13589 2D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 1D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 2D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 3Genetic Discovery May Improve Hepatitis C Treatment 54618 1Genetic Discovery May Improve Hepatitis C Treatment 54618 2
...ehensive overview of clinical trials, ...AGO, Aug. 13 Aon eSolutions, the client,technolog...ding provider of,global risk and insurance solutio... Trials module as part of RiskConsole, the market-...system (RMIS)., (Logo: http://www.newscom.com/cg...
... could provide therapeutic benefit in c...ARLSBAD, Calif., Aug. 13 Isis,Pharmaceuticals, In...ed a,Phase 1 study of ISIS 353512, an antisense dr...ein (CRP). CRP levels are frequently elevated,in p...ovascular disease,Crohn,s disease, rheumatoid arth...
Other Medicine Technology:Aon eSolutions Launches Clinical Trials Module 2Aon eSolutions Launches Clinical Trials Module 3Aon eSolutions Launches Clinical Trials Module 4Isis Initiates Clinical Trial of CRP Drug 2Isis Initiates Clinical Trial of CRP Drug 3
(Date:11/27/2009)...lus low-emission vehicles may reduce future diseas...v. 27 (HealthDay News) -- Encouraging city dweller...offer much greater public health benefits than inc...hers have found. , The study compared the proje...and transport scenarios for London, England, and D...
(Date:11/27/2009)... Multi-purpose bilingual coloring books design...the business community to educate - inform parents...Safety issues to Dinosuars to ABC,S and a host of ...is, MO (PRWEB) November 27, 2009 -- Today’s ...to keep them busy any hour of the day, but one of ...
(Date:11/26/2009)....,Nov.27/PRNewswire/--ThediabetespopulationintheUn...ualmedicalspendingonthediseaseisprojectedtohit$336...blishedintheDecemberissueof DiabetesCare .TheNatio...fNovoNordisk,commissionedtheanalysisbyateamfromthe...thenumberofAmericanslivingwithdiabeteswillrisefrom...
(Date:11/26/2009)...ill when on an emotional rollercoaster, study find... -- Call it the fear factor meets the jubilant spo... -- especially those who root for the winning team...ely contested match and victory was in doubt, prod...w on that this Thanksgiving weekend as you,re glue...
(Date:11/26/2009)... Benton Communications announces a highly effe...r retailers struggling to make an economic recover... 2009 -- Flu fears is the type of challenge that c...om, according to Dr. David Benton, business growth...growth system – The Rfactor Intensive . &...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2
...crucial decision taken to delay action on Barr Pha...the FDA chief did not take two senior officials op...n sued by the non-profit Center for Reproductive R...he wanted to approve the drug. Still, in Galson’s ...
...bid to save its plummeting sales of chicken produc...vertisement campaign. //The campaign would ensure ...here is safe. This has been planned by McDonald... influence the customers. They have already pre...
...eservations are slowly thought to be extended to a...nal courses. The decision taken by the Maharashtra...rivate institutions. // They say that reservation...ntal Colleges of Maharashtra (AMUPMDCM) asked the ...
...dy that was published in Urology Journal BJUI Inte...ill wet the bed and almost half of 19-year-olds wh...// Researchers from the Chinese University o... researchers found that almost 3% of the children ...
...ny states of u.s., mothers who breastfed their bab...ncy. // As no act was made to prove that breastfee... safe for both mother and child. The U.S. ...alth Organization recommends that babies be breast...
...c, the popular drug for depression has been studie... in the brain. Researchers from the Cold Spring Ha...ound that the drug causes the production of immatu...ir study, analyzed proteins that were produced by ...
Other Medicine News:Health News:Breastfeeding Mothers Arrested For Public Indecency 2
Nerve Hook - Right
Single Skin Hook
Smith Expressor Hook
Osher "Y" Hook
Medicine Products: